ATE420355T1 - Diagnostik für übertragbare spongiforme enzephalopathie - Google Patents

Diagnostik für übertragbare spongiforme enzephalopathie

Info

Publication number
ATE420355T1
ATE420355T1 AT01127425T AT01127425T ATE420355T1 AT E420355 T1 ATE420355 T1 AT E420355T1 AT 01127425 T AT01127425 T AT 01127425T AT 01127425 T AT01127425 T AT 01127425T AT E420355 T1 ATE420355 T1 AT E420355T1
Authority
AT
Austria
Prior art keywords
cells
cell
spongiform encephalopathy
diagnostics
infective
Prior art date
Application number
AT01127425T
Other languages
English (en)
Inventor
Adriano Aguzzi
Michael A Klein
Alex Raeber
Charles Weissmann
Rolf Zinkernagel
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE420355T1 publication Critical patent/ATE420355T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
AT01127425T 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie ATE420355T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97122186A EP0931551B1 (de) 1997-12-16 1997-12-16 Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte
EP01127425A EP1215497B1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme Enzephalopathie

Publications (1)

Publication Number Publication Date
ATE420355T1 true ATE420355T1 (de) 2009-01-15

Family

ID=8227810

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01127424T ATE427120T1 (de) 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten
AT97122186T ATE358497T1 (de) 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte
AT01127425T ATE420355T1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT01127424T ATE427120T1 (de) 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten
AT97122186T ATE358497T1 (de) 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte

Country Status (9)

Country Link
US (1) US20080063600A1 (de)
EP (4) EP1215497B1 (de)
JP (1) JP2002508335A (de)
AT (3) ATE427120T1 (de)
AU (1) AU2613199A (de)
CA (1) CA2348660A1 (de)
DE (3) DE69737557T2 (de)
ES (3) ES2324334T3 (de)
WO (1) WO1999030738A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053838A2 (en) * 1997-05-30 1998-12-03 Winnacker Ernst Ludwig A soluble laminin receptor precursor and methods to inhibit its interactions
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
GB0110172D0 (en) * 2001-04-25 2001-06-20 Pa Consulting Services Improved analytical test approach for blood
EP1921451A3 (de) 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
US20070166735A1 (en) * 2005-12-08 2007-07-19 South Dakota State University Methods of in vitro propagation and detection of infectious prion
US7601506B2 (en) 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
JP2010530857A (ja) * 2007-06-22 2010-09-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 神経系障害、特に感染性海綿状脳症及びアルツハイマー病を治療するためのｃｄ５２抗原に対する抗体の使用
RU2368905C1 (ru) * 2008-07-11 2009-09-27 Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи Способ диагностики степени тяжести диабетической энцефалопатии у детей и подростков
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
JP6612227B2 (ja) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
ES2954311T3 (es) 2017-04-01 2023-11-21 Avm Biotechnology Llc Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273882A (en) 1985-06-13 1993-12-28 Amgen Method and kit for performing nucleic acid hybridization assays
US5055290A (en) 1985-12-18 1991-10-08 Boehringer Mannehim Gmbh Ciamexone as a selective immunosuppressant
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
US5369119A (en) 1988-07-28 1994-11-29 Boehringer Mannheim Gmbh Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
EP1416280A3 (de) * 1995-09-14 2005-08-10 The Regents of the University of California Antikörper spezifisch für natives PrPsc
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
DE69737557D1 (de) 2007-05-16
JP2002508335A (ja) 2002-03-19
WO1999030738A3 (en) 1999-10-21
EP1214943B1 (de) 2009-04-01
ES2320314T3 (es) 2009-05-21
EP1044020A2 (de) 2000-10-18
EP0931551A1 (de) 1999-07-28
ATE358497T1 (de) 2007-04-15
EP1215497B1 (de) 2009-01-07
US20080063600A1 (en) 2008-03-13
WO1999030738A2 (en) 1999-06-24
EP1215497A1 (de) 2002-06-19
CA2348660A1 (en) 1999-06-24
DE69739210D1 (de) 2009-02-26
ES2285720T3 (es) 2007-11-16
EP0931551B1 (de) 2007-04-04
ES2324334T3 (es) 2009-08-05
DE69739344D1 (de) 2009-05-14
EP1214943A1 (de) 2002-06-19
DE69737557T2 (de) 2007-12-20
AU2613199A (en) 1999-07-05
ATE427120T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
DE69739210D1 (de) Diagnostik für übertragbare spongiforme Enzephalopathie
Caul Small round structured viruses: airborne transmission and hospital control.
CY1107550T1 (el) Συνδυαστικα εμβολια μηνιγγιτιδας b/c
BR9712289A (pt) Composições e métodos para o tratamento de infecções virais
DE69840383D1 (de) Ctl epitope des epstein-barr virus
FI875326A7 (fi) Valonsäteilyttäjälaite korvan lääketieteelliseen hoitoon.
DK0499923T3 (da) Dentaladhæsiv
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ES495939A0 (es) Un procedimiento de preparacion de una vacuna de virus vivosde la peritonitis infecciosa de los felinos
DK0484438T3 (da) Biologisk præparat og dets anvendelse
HK1041434A1 (zh) 抗病毒药物和乙型肝炎疫苗的联合
NO910869D0 (no) Fremgangsmaate for desinfeksjon av medisinsk avstoepningsmasse.
DE10075036I1 (de) Impfstoff und Diagnostikum fuer den Schweine-cholera-virus
Bach et al. Acute toxoplasmic encephalitis in a normal adult
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
ATE281173T1 (de) Behandlung einer virusinfektion bei schweinen
DK0516725T3 (da) Ny anvendelse af Linomide
FR2712493B1 (fr) Utilisation de photosensibilisateurs dérivés du noyau phorbine pour la décontamination du sang infecté par des parasites et/ou des virus.
ATE80553T1 (de) Behandlung von viraler infektion.
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
FR2716104B1 (fr) Protection microbiologique à usage unique de la membrane du stéthoscope médical.
HUP9901488A2 (hu) Kontrasztanyagok
SU1487856A1 (ru) Стоматологическое зеркало а. м. асриева
Kissinger Geneva conference points out problems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties